Rheostat Therapeutics Raises $23 Million from Heavyweight Pharma Companies in Series A Round

Rheostat Therapeutics Raises $23 Million from Heavyweight Pharma Companies in Series A Round

Source: 
CP Wire
snippet: 
  • Merck, Abbvie and Amgen VC groups participated
  • Rheostat is focused on developing novel treatments for neurodegeneration, cognition and rare diseases